致敏肾移植受者同种异体抗体产生的机制

肾移植是终末期肾脏病患者最佳的治疗方法。体内存在高水平的供者特异性抗体(DSA)的致敏受者接受肾移植后,早期体液性排斥反应发生率高、移植物长期存活率低。致敏肾移植受者同种异体抗体主要由终末分化的长寿命浆细胞在骨髓和其他次级淋巴组织中产生。移植后受者对同种异体抗原并不全发生记忆反应,只有不到一半的致敏受者有同种异体抗体水平增加。移植后早期高水平的同种异体抗体产生将导致AHR;移植后的晚期DSA消失可能与预存浆细胞消失,DSA被移植物吸收或血清存在阻断因子等因素相关。明确移植后不同时期同种异体抗体产生的机制,有助于我们设计更好的治疗方案改善致敏受者移植术后的预后。

Mechanisms of alloantibody production in sensitized renal allograft recipients

Renal transplantation is the best protocol for the patients of ESRD.While clinical protocols have been developed to allow for kidney transplantation in the patient with high levels of donor-specific alloantibody(DSA),the significant limitations still exist including high rates of early humoral rejection and decreased long-term graft survival.It seems that alloantibody production at baseline is primarily the product of terminally differentiated long-lived PC in the bone marrow and other secondary lymphoid ti...